Literature DB >> 12740155

The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France.

Mireille Bonierbale1, Christophe Lançon, Jean Tignol.   

Abstract

OBJECTIVES: This survey was conducted in order to determine the extent and nature of disorders of sexual function in depressed patients treated in the community in France.
METHODS: Patients with DSM-IV major depressive episodes were included. The inclusion criteria stipulated that only patients with no antecedents of sexual dysfunction could be included. Information on sexual function was collected with a questionnaire which included physician observations as well as the Arizona Sexual Experience Scale.
RESULTS: Overall, 4557 patients were included in the study. The prevalence of disorders of sexual function observed was 35% for spontaneously reported problems and 69% for problems identified by physician questioning. Impaired sexual function in depressed patients is also revealed by a high score on the Arizona Sexual Experience Scale (mean overall score of 21.4). Frequency of sexual dysfunction was somewhat higher in patients treated with antidepressants than in untreated patients (71% and 65% respectively). Treatment with tianeptine was associated with a lower incidence of sexual dysfunction than was treatment with tricyclic antidepressants or with selective serotonin reuptake inhibitors. Although in 39% of cases, physicians managed the sexual problems encountered by changing the antidepressant treatment, the most frequently adopted approach (42% of cases) was to await spontaneous remission. Drug holidays or adjunctive therapy were very rarely proposed.
CONCLUSIONS: The prevalence of sexual dysfunction in patients with major depression is high. Antidepressant drugs appear to aggravate such problems, with certain classes of drug better tolerated than others. Sexual dysfunction in depressed patients is often not optimally treated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740155     DOI: 10.1185/030079902125001461

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  40 in total

1.  [Adverse side-effect on sexual function caused by psychotropic drugs and psychotropic substances].

Authors:  S Cohen; K U Kühn; B Sträter; N Scherbaum; W Weig
Journal:  Nervenarzt       Date:  2010-09       Impact factor: 1.214

2.  Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy.

Authors:  Jessica L Chan; Suneeta Senapati; Lauren N C Johnson; Laura DiGiovanni; Chan Voong; Samantha F Butts; Susan M Domchek
Journal:  Menopause       Date:  2019-02       Impact factor: 2.953

3.  Sexual function in postpartum women treated for depression: results from a randomized trial of nortriptyline versus sertraline.

Authors:  Teresa Lanza di Scalea; Barbara H Hanusa; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2009-03-09       Impact factor: 4.384

4.  Major depressive disorder, obsessive-compulsive disorder, and generalized anxiety disorder: do the sexual dysfunctions differ?

Authors:  Arvind Kendurkar; Brinder Kaur
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 5.  Neurobiological and clinical effects of the antidepressant tianeptine.

Authors:  Siegfried Kasper; Bruce S McEwen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Prevalence of Sexual Dysfunction in Women with Multiple Sclerosis: a Systematic Review and Meta-Analysis.

Authors:  Amirreza Azimi; Sara Hanaei; Mohammad Ali Sahraian; Mehdi Mohammadifar; Sreeram V Ramagopalan; Mahsa Ghajarzadeh
Journal:  Maedica (Buchar)       Date:  2019-12

7.  Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study.

Authors:  James A Blumenthal; Andrew Sherwood; Michael A Babyak; Lana L Watkins; Patrick J Smith; Benson M Hoffman; C Virginia F O'Hayer; Stephanie Mabe; Julie Johnson; P Murali Doraiswamy; Wei Jiang; Douglas D Schocken; Alan L Hinderliter
Journal:  J Am Coll Cardiol       Date:  2012-08-01       Impact factor: 24.094

Review 8.  Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.

Authors:  Sidney H Kennedy; Sakina J Rizvi
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

9.  Tianeptine: an antidepressant with memory-protective properties.

Authors:  Phillip R Zoladz; Collin R Park; Carmen Muñoz; Monika Fleshner; David M Diamond
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

Review 10.  The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.

Authors:  B S McEwen; S Chattarji; D M Diamond; T M Jay; L P Reagan; P Svenningsson; E Fuchs
Journal:  Mol Psychiatry       Date:  2009-08-25       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.